Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2017

View Archived Issues

Galapagos initiates phase I trial of cystic fibrosis C2 corrector GLPG-3221

First subject dosed in phase III study of Nevakar's ophthalmic solution for myopia in children

Novel COMT inhibitors as candidates for dopaminergic-related cognitive and motor deficits

BTRX-335140, a potent and reversible KOR antagonist with promising in vivo activity

LDN/OSU-215111 shows promise in preclinical models of Alzheimer's disease and Gulf War illness

Beactica receives funding to develop novel and potent allosteric LSD1 modulators

Supplemental NDA seeks to expand Trelegy Ellipta label in U.S.

Prometic Life Sciences reports interim data from IVIG phase III trial

Teijin's TEI-A reduces uric acid levels in preclinical tests

Rupafin set for Japanese launch

Shionogi & Co. patents new AMPK activators for diabetes

Phase II trials of milciclib in thymic carcinoma and thymoma meet primary endpoints

Bavencio launched in Japan

Perrigo completes divestiture of API business

Innate Pharma offers update on lirilumab program

Sage Therapeutics discloses novel NMDA receptor modulators

Shenogen Pharma and Lee's Pharm collaborate to develop combination product for late-stage cancer

Fochon Pharma presents novel CDK4/6 inhibitors

DSMB recommends continuation of RESOLVE-IT study of elafibranor in NASH

Immunovaccine discloses vaccine compositions for cancer

European Commission approves Tremfya

New vasopressin receptor antagonists presented by Bayer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...